Orphan drugs to grow twice as fast as rest of the industry: report
Despite the focus on high drug prices, orphan drugs are expected to grow at double the rate of the rest of the pharmaceutical industry over the next six years.
The two diabetes rivals air competing TV spots as they compete for GLP-1 supremacy.
Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.
Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.